New obesity combo aims to preserve muscle while shedding fat
NCT ID NCT07671391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding LAE102 to the weight-loss drug tirzepatide can improve body composition in 60 adults with obesity. Participants receive weekly injections of either LAE102 plus tirzepatide or a placebo plus tirzepatide. The main goal is to see if the combination increases lean body mass after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAE102 injection and tirzepatide
What this could lead to
If it works, this combination could help people with obesity lose fat while preserving or increasing muscle mass, improving overall body composition.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The added benefit of LAE102 over tirzepatide alone is unproven, and side effects are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY ADULT ONSET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••